The use of dendritic cells to immunize against tumor antigens is improving the prospects for cancer vaccines. However, caution must be taken to avoid activating autoimmunity against normal cells (pages 1011–1017).
This is a preview of subscription content, log in via an institution to check access.
References
Kugler, A. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med. 6, 332–336 (2000).
Nair, S.K. et al. Induction of cytotoxic responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells . Nature Med. 6, 1011–1017 (2000).
Brocker, T. et al. Targeted expression of major histocompatibility complex class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J. Exp. Med. 185, 541–550 (1997).
Ludewig, B. et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease . J. Exp. Med. 191, 795– 803 (2000).
Siegal, F.P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835– 1837 (1999).
Rissoan, M.C. et al. Reciprocal control of T helper cell and dendritic cell differentiation . Science 283, 1183–11186 (1999).
Biragyn, A., Tani, K., Grimm, M.C., Weeks, S. & Kwak, L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nature Biotech. 17, 253–258 ( 1999).
Kim, N.W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011– 2013 (1994).
Weng, N.P. et al. Regulated expression of telomerase activity in human T lymphocyte development and activity. J. Exp. Med. 183, 2471–2479 (1996).
Vonderheide, R.H. et al. The telomerase catalitic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673–679 (1999).
Minev, B. et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA 97, 4796–4801 (2000).
Bendandi, M. et al. Complete molecular remission induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med. 5, 1171–1177 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Biragyn, A., Kwak, L. Designer cancer vaccines are still in fashion. Nat Med 6, 966–968 (2000). https://doi.org/10.1038/79649
Issue Date:
DOI: https://doi.org/10.1038/79649
- Springer Nature America, Inc.
This article is cited by
-
In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2
Journal of Translational Medicine (2011)
-
Anaplastic lymphoma kinase: an oncogene for tumor vaccination
Journal of Molecular Medicine (2009)
-
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Nature Medicine (2008)
-
Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture
Cancer Immunology, Immunotherapy (2006)
-
Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
Leukemia (2004)